Evidence map›Paper›PMID 33875663›Full record

ArticleNature communications2021

STING enhances cell death through regulation of reactive oxygen species and DNA damage.

Thomas J Hayman, Marta Baro, Tyler MacNeil, Chatchai Phoomak, Thazin Nwe Aung, Wei Cui, Kevin Leach, Radhakrishnan Iyer, Sreerupa Challa, Teresa Sandoval-Schaefer and 3 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers.

0numbers the graph read from it
0cells of the map it votes in
117citing papers in PubMed
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

117 citing papers in PubMed, 199 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

57 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Thomas J HaymanDepartment of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0001-7046-2276
Marta BaroDepartment of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, USA.
Tyler MacNeilDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA.
Chatchai PhoomakDepartment of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0002-3808-8816
Thazin Nwe AungDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA.
Wei CuiDepartment of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, USA.
Kevin LeachF-Star Therapeutics, Cambridge, MA, USA.
Radhakrishnan IyerF-Star Therapeutics, Cambridge, MA, USA.
Sreerupa ChallaF-Star Therapeutics, Cambridge, MA, USA.
Teresa Sandoval-SchaeferMolecular, Cellular and Developmental Biology, Yale University, New Haven, CT, USA.
Barbara A BurtnessDepartment of Medicine, Yale School of Medicine, New Haven, CT, USA.
David L RimmDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0001-5820-4397
Joseph N ContessaDepartment of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, USA. Joseph.Contessa@yale.edu.ORCID 0000-0001-9408-1865
Yale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Yale Head and Neck Cancer SPORE: Overcoming Treatment Resistance in Head and Neck CancerP50DE030707 · NIDCR · YALE UNIVERSITY · PI BURTNESS, BARBARA · 2020 to 2024
$11.8M
YALE CANCER CENTER CALABRESI IMMUNO-ONCOLOGY TRAINING PROGRAMK12CA215110 · NCI · YALE UNIVERSITY · PI Harriet M. Kluger · 2018 to 2026
$6.1M
NCATS NIH HHS UL1 TR001863NCI NIH HHS K12 CA215110NIDCR NIH HHS P50 DE030707
6 · The paper itself

Abstract

Resistance to DNA-damaging agents is a significant cause of treatment failure and poor outcomes in oncology. To identify unrecognized regulators of cell survival we performed a whole-genome CRISPR-Cas9 screen using treatment with ionizing radiation as a selective pressure, and identified STING (stimulator of interferon genes) as an intrinsic regulator of tumor cell survival. We show that STING regulates a transcriptional program that controls the generation of reactive oxygen species (ROS), and that STING loss alters ROS homeostasis to reduce DNA damage and to cause therapeutic resistance. In agreement with these data, analysis of tumors from head and neck squamous cell carcinoma patient specimens show that low STING expression is associated with worse outcomes. We also demonstrate that pharmacologic activation of STING enhances the effects of ionizing radiation in vivo, providing a rationale for therapeutic combinations of STING agonists and DNA-damaging agents. These results highlight a role for STING that is beyond its canonical function in cyclic dinucleotide and DNA damage sensing, and identify STING as a regulator of cellular ROS homeostasis and tumor cell susceptibility to reactive oxygen dependent, DNA damaging agents.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsCell Line, TumorDNA DamageFemaleHEK293 CellsHumansKaplan-Meier EstimateMembrane ProteinsMiceMice, Inbred C57BLMice, NudeReactive Oxygen SpeciesSquamous Cell Carcinoma of Head and NeckSTING ProteinXenograft Model Antitumor AssaysMembrane ProteinsReactive Oxygen SpeciesSTING1 protein, humanSTING Protein

Identifiers

PMID33875663
PMCPMC8055995
OpenAlexW3154083166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.